Monoclonal Antibody Treatments Shown Safe for HIV and Other Indications with Dr. Nader Pourhassan CytoDyn

Published: Jan. 6, 2020, 5:21 p.m.

Dr. Nader Pourhassan, is Director, President, and CEO, CytoDyn, a late-stage biotechnology company developing leronlimab (PRO 140), a targeted therapy with the potential to treat multiple diseases.\xa0 Nader highlights CytoDyn's ongoing clinical trial evaluating leronlimab for metastatic triple negative breast cancer (mTNBC) and the company's plans to submit a Biologics License Agreement (BLA) to the U.S. Food and Drug Administration (FDA) for leronlimab in combination with highly active antiretroviral therapy (HAART) to treat patients suffering from HIV.

@CytoDyn

#HIV\xa0 #mTNBC\xa0 #TNBC\xa0 #Leronlimab

CytoDyn.com

Download the transcript here

\xa0